Bioxytran Inc (BIXT)

[hazarderk]

BioXyTran Inc. is a biotech company that has recently announced positive results from a clinical trial of its COVID-19 antiviral drug, ProLectin-M. The trial showed that the drug was able to completely eliminate the virus in 100% of patients by day 7 and in 88% of patients by day 3. The drug works by blocking the viral docking of the virus to target cells, rather than by blocking viral replication from the inside, and is taken orally. BioXyTran has a strong background in carbohydrate chemistry and was able to pivot towards developing a carbohydrate-based antiviral for COVID-19 during the beginning of the pandemic. The company has faced adversity, including being suspended by the SEC and defaulting on debt, but has managed to regain trading status and secure backing from private equity and high-net-worth individuals. The potential success of ProLectin-M could have significant impact on the market for antivirals and on BioXyTran's valuation.